Literature DB >> 18987353

A multidisciplinary study of patients with early-onset PD with and without parkin mutations.

E Lohmann1, S Thobois, S Lesage, E Broussolle, S Tezenas du Montcel, M-J Ribeiro, P Remy, A Pelissolo, B Dubois, L Mallet, P Pollak, Y Agid, A Brice.   

Abstract

OBJECTIVE: To establish phenotype-genotype correlations in early-onset Parkinson disease (EOPD), we performed neurologic, neuropsychological, and psychiatric evaluations in a series of patients with and without parkin mutations.
BACKGROUND: Parkin (PARK2) gene mutations are the major cause of autosomal recessive parkinsonism. The usual clinical features are early-onset typical PD with a slow clinical course, an excellent response to low doses of levodopa, frequent treatment-induced dyskinesias, and the absence of dementia.
METHODS: A total of 44 patients with EOPD (21 with and 23 without parkin mutations) and 9 unaffected single heterozygous carriers of parkin mutations underwent extensive clinical, neuropsychological, and psychiatric examinations.
RESULTS: The neurologic, neuropsychological, and psychiatric features were similar in all patients, except for significantly lower daily doses of dopaminergic treatment and greater delay in the development of levodopa-related fluctuations (p < 0.05) in parkin mutation carriers compared to noncarriers. There was no major difference between the two groups in terms of general cognitive efficiency. Psychiatric manifestations (depression) were more frequent in patients than in healthy single heterozygous parkin carriers but did not differ between the two groups of patients.
CONCLUSION: Carriers of parkin mutations are clinically indistinguishable from other patients with young-onset Parkinson disease (PD) on an individual basis. Severe generalized loss of dopaminergic neurons in the substantia nigra pars compacta in these patients is associated with an excellent response to low doses of dopa-equivalent and delayed fluctuations, but cognitive impairment and special behavioral or psychiatric symptoms were not more severe than in other patients with early-onset PD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18987353      PMCID: PMC2677494          DOI: 10.1212/01.wnl.0000327098.86861.d4

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  23 in total

1.  Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene.

Authors:  R Hilker; C Klein; M Ghaemi; B Kis; T Strotmann; L J Ozelius; O Lenz; P Vieregge; K Herholz; W D Heiss; P P Pramstaller
Journal:  Ann Neurol       Date:  2001-03       Impact factor: 10.422

2.  Association between early-onset Parkinson's disease and mutations in the parkin gene.

Authors:  C B Lücking; A Dürr; V Bonifati; J Vaughan; G De Michele; T Gasser; B S Harhangi; G Meco; P Denèfle; N W Wood; Y Agid; A Brice
Journal:  N Engl J Med       Date:  2000-05-25       Impact factor: 91.245

3.  The nigrostriatal dopaminergic system in familial early onset parkinsonism with parkin mutations.

Authors:  A T Portman; N Giladi; K L Leenders; P Maguire; L Veenma-van der Duin; J Swart; J Pruim; E S Simon; S Hassin-Baer; A D Korczyn
Journal:  Neurology       Date:  2001-06-26       Impact factor: 9.910

4.  Parkin mutations are frequent in patients with isolated early-onset parkinsonism.

Authors:  Magali Periquet; Morwena Latouche; Ebba Lohmann; Nina Rawal; Giuseppe De Michele; Sylvain Ricard; Hélio Teive; Valérie Fraix; Marie Vidailhet; David Nicholl; Paolo Barone; Nick W Wood; Salmo Raskin; Jean-François Deleuze; Yves Agid; Alexandra Dürr; Alexis Brice
Journal:  Brain       Date:  2003-06       Impact factor: 13.501

5.  Autosomal recessive early-onset parkinsonism with diurnal fluctuation: clinicopathologic characteristics and molecular genetic identification.

Authors:  Y Yamamura; N Hattori; H Matsumine; S Kuzuhara; Y Mizuno
Journal:  Brain Dev       Date:  2000-09       Impact factor: 1.961

Review 6.  Alpha-synuclein and Parkinson's disease.

Authors:  C B Lücking; A Brice
Journal:  Cell Mol Life Sci       Date:  2000-12       Impact factor: 9.261

7.  Rare heterozygous parkin variants in French early-onset Parkinson disease patients and controls.

Authors:  S Lesage; E Lohmann; F Tison; F Durif; A Dürr; A Brice
Journal:  J Med Genet       Date:  2007-08-31       Impact factor: 6.318

8.  Complex relationship between Parkin mutations and Parkinson disease.

Authors:  Andrew West; Magali Periquet; Sarah Lincoln; Christoph B Lücking; David Nicholl; Vincenzo Bonifati; Nina Rawal; Thomas Gasser; Ebba Lohmann; Jean-François Deleuze; Demetrius Maraganore; Allan Levey; Nick Wood; Alexandra Dürr; John Hardy; Alexis Brice; Matt Farrer
Journal:  Am J Med Genet       Date:  2002-07-08

9.  Clinical, 18F-dopa PET, and genetic analysis of an ethnic Chinese kindred with early-onset parkinsonism and parkin gene mutations.

Authors:  Ruey-Meei Wu; Din-E Shan; Chen-Ming Sun; Ren-Shyan Liu; Wuh-Liang Hwu; Chun-Hwei Tai; Jennifer Hussey; Andrew West; Katrina Gwinn-Hardy; John Hardy; Judy Chen; Matt Farrer; Sarah Lincoln
Journal:  Mov Disord       Date:  2002-07       Impact factor: 10.338

10.  Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study.

Authors:  Naheed L Khan; David J Brooks; Nicola Pavese; Mary G Sweeney; Nicholas W Wood; Andrew J Lees; Paola Piccini
Journal:  Brain       Date:  2002-10       Impact factor: 13.501

View more
  27 in total

1.  The relationship between obsessive-compulsive symptoms and PARKIN genotype: The CORE-PD study.

Authors:  Madeleine E Sharp; Elise Caccappolo; Helen Mejia-Santana; Ming-X Tang; Llency Rosado; Martha Orbe Reilly; Diana Ruiz; Elan D Louis; Cynthia Comella; Martha Nance; Susan Bressman; William K Scott; Caroline Tanner; Cheryl Waters; Stanley Fahn; Lucien Cote; Blair Ford; Michael Rezak; Kevin Novak; Joseph H Friedman; Ronald Pfeiffer; Haydeh Payami; Eric Molho; Stuart A Factor; John Nutt; Carmen Serrano; Maritza Arroyo; Michael W Pauciulo; William C Nichols; Lorraine N Clark; Roy N Alcalay; Karen S Marder
Journal:  Mov Disord       Date:  2014-11-12       Impact factor: 10.338

2.  Altered hippocampal synaptic physiology in aged parkin-deficient mice.

Authors:  Jesse E Hanson; Adrienne L Orr; Daniel V Madison
Journal:  Neuromolecular Med       Date:  2010-03-16       Impact factor: 3.843

3.  Neuropsychological Profile of Parkin Mutation Carriers with and without Parkinson Disease: The CORE-PD Study.

Authors:  Elise Caccappolo; Roy N Alcalay; Helen Mejia-Santana; Ming-X Tang; Brian Rakitin; Llency Rosado; Elan D Louis; Cynthia L Comella; Amy Colcher; Danna Jennings; Martha A Nance; Susan Bressman; William K Scott; Caroline M Tanner; Susan F Mickel; Howard F Andrews; Cheryl Waters; Stanley Fahn; Lucien J Cote; Steven Frucht; Blair Ford; Michael Rezak; Kevin Novak; Joseph H Friedman; Ronald F Pfeiffer; Laura Marsh; Brad Hiner; Andrew D Siderowf; Barbara M Ross; Miguel Verbitsky; Sergey Kisselev; Ruth Ottman; Lorraine N Clark; Karen S Marder
Journal:  J Int Neuropsychol Soc       Date:  2010-11-24       Impact factor: 2.892

4.  Phenotype analysis in patients with early onset Parkinson's disease with and without parkin mutations.

Authors:  Hee Jin Kim; Han-Joon Kim; Jee-Young Lee; Ji Young Yun; So Yeon Kim; Sung Sup Park; Beom S Jeon
Journal:  J Neurol       Date:  2011-05-29       Impact factor: 4.849

5.  Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease.

Authors:  Roy N Alcalay; Helen Mejia-Santana; Ming X Tang; Brian Rakitin; Llency Rosado; Barbara Ross; Miguel Verbitsky; Sergey Kisselev; Elan D Louis; Cynthia L Comella; Amy Colcher; Danna Jennings; Martha A Nance; Susan Bressman; William K Scott; Caroline Tanner; Susan F Mickel; Howard F Andrews; Cheryl H Waters; Stanley Fahn; Lucien J Cote; Steven J Frucht; Blair Ford; Michael Rezak; Kevin Novak; Joseph H Friedman; Ronald Pfeiffer; Laura Marsh; Bradley Hiner; Andrew Siderowf; Ruth Ottman; Lorraine N Clark; Karen S Marder; Elise Caccappolo
Journal:  J Clin Exp Neuropsychol       Date:  2010-02-24       Impact factor: 2.475

6.  A Peruvian family with a novel PARK2 mutation: Clinical and pathological characteristics.

Authors:  Mario R Cornejo-Olivas; Luis Torres; Ignacio F Mata; Pilar Mazzetti; Diana Rivas; Carlos Cosentino; Miguel Inca-Martinez; Juan M Cuba; Cyrus P Zabetian; James B Leverenz
Journal:  Parkinsonism Relat Disord       Date:  2015-01-15       Impact factor: 4.891

7.  Mechanisms of genomic instabilities underlying two common fragile-site-associated loci, PARK2 and DMD, in germ cell and cancer cell lines.

Authors:  Jun Mitsui; Yuji Takahashi; Jun Goto; Hiroyuki Tomiyama; Shunpei Ishikawa; Hiroyo Yoshino; Narihiro Minami; David I Smith; Suzanne Lesage; Hiroyuki Aburatani; Ichizo Nishino; Alexis Brice; Nobutaka Hattori; Shoji Tsuji
Journal:  Am J Hum Genet       Date:  2010-07-09       Impact factor: 11.025

8.  Variable phenotypic expression in families with early-onset Parkinsonism due to PRKN mutations.

Authors:  Siamak Karkheiran; Catharine E Krebs; Hossein Darvish; Mojgan Asadian; Gholam Ali Shahidi; Coro Paisán-Ruiz
Journal:  J Neurol       Date:  2014-04-30       Impact factor: 4.849

9.  The relation between depression and parkin genotype: the CORE-PD study.

Authors:  A Srivastava; M-X Tang; H Mejia-Santana; L Rosado; E D Louis; E Caccappolo; C Comella; A Colcher; A Siderowf; D Jennings; M Nance; S Bressman; W K Scott; C Tanner; S Mickel; H Andrews; C Waters; S Fahn; L Cote; S Frucht; B Ford; R N Alcalay; B Ross; M Orbe Reilly; M Rezak; K Novak; J H Friedman; R D Pfeiffer; L Marsh; B Hiner; D Merle; R Ottman; L N Clark; K Marder
Journal:  Parkinsonism Relat Disord       Date:  2011-12       Impact factor: 4.891

10.  Cognitive and motor function in long-duration PARKIN-associated Parkinson disease.

Authors:  Roy N Alcalay; Elise Caccappolo; Helen Mejia-Santana; Ming Xin Tang; Llency Rosado; Martha Orbe Reilly; Diana Ruiz; Elan D Louis; Cynthia L Comella; Martha A Nance; Susan B Bressman; William K Scott; Caroline M Tanner; Susan F Mickel; Cheryl H Waters; Stanley Fahn; Lucien J Cote; Steven J Frucht; Blair Ford; Michael Rezak; Kevin E Novak; Joseph H Friedman; Ronald F Pfeiffer; Laura Marsh; Bradley Hiner; Haydeh Payami; Eric Molho; Stewart A Factor; John G Nutt; Carmen Serrano; Maritza Arroyo; Ruth Ottman; Michael W Pauciulo; William C Nichols; Lorraine N Clark; Karen S Marder
Journal:  JAMA Neurol       Date:  2014-01       Impact factor: 18.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.